Mussalam Alabdullah
General Medical Council, UKPresentation Title:
XRCC1-ligase III heterodimer tissue expression can impact the clinicopathological and prognostic value of patients with primary surgically resected ovarian cancer
Abstract
Background: In gynaecologic malignancy, Ovarian Cancer (OC) is the leading cause of death. The standard initial treatment for OC patients is still the platinum-based chemotherapy. Platinum resistance and recurrence is a formidable problem that impacts clinical outcomes in OC patients. XRCC1-Ligase III heterodimer is a key player in DNA base excision repair (BER), Single Strand Break Repair (SSBR) and Alternative Non-Homologous End Joining (alt-NHEJ) pathway for double strand breaks (DSBs). Our objective was to evaluate if XRCC1-ligase III expressions could predict platinum and clinical outcome in epithelial ovarian cancers.
Methods: After collecting the tissue microarrays of 525 consecutive ovarian epithelial cancer cases between 1997 and 2010, investigation of the expression of XRCC1 and Ligase III was carried out. Then, their expression was correlated to clinicopathological outcomes as well as to Recurrence Free Survival (RFS) and Ovarian Cancer Specific Survival (OCSS).
Results: High nuclear XRCC1 expression was significantly associated with serous cystadenocarcinomas (p = 0.0000), higher FIGO stage at presentation (p = 0.001), residual tumour following surgery (p = 0.038), measurable disease before chemotherapy (p= 0.002) and platinum resistance (p = 0.002). High cytoplasmic ligase III expression was significantly associated with higher FIGO stage (p = 0.002), higher histology grade (p = 0.028), residual tumour following surgery (p = 0.001), measurable disease before chemotherapy (p= 0.006) and platinum resistance (p = 0.025). High nuclear staining was significantly associated with serous cystadenocarcinomas (p = 0.017). High XRCC1 was significantly positively highly correlated with high nuclear LIG3 (p < 0.0000). High XRCC1 and LIG III protein expressions were correlated with poor outcome.
Conclusions: XRCC1-Ligase III heterodimer is a promising predictive biomarker of platinum response in epithelial ovarian cancer.
Biography
Mussalam Layth Alobaidy is a UK-trained Surgeon specializing in pediatric general, laparoscopic, and oncologic surgery. He holds a PhD in oncology from the University of Nottingham and has trained extensively within the UK’s NHS system, where he developed advanced expertise in minimally invasive and cancer-related procedures. His international clinical background is grounded in the highest standards of surgical care and multidisciplinary oncology practice. He is currently serving as a lecturer at the university together with his commitments as a Surgeon. He is an appointed Examiner at the General Medical Council (GMC) in the United Kingdom, playing a vital role in maintaining the integrity and quality of the UK medical profession. He is a frequent participant in national and international conferences. He is known for his dedication to surgical education, innovation in cancer care, and global collaboration in advancing surgical standards.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Drop us an email for Program enquiry
cancer@scientexevents.com
Registration Query
finance@scientexconferences.com
General Queries
contact@scientexconferences.com
cancer@scientexconferences.com
Our Social Presence
Call us at
USA : (+1) 312 815 4231